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Introduction. The quality of life (QoL) is an important outcome 
indicator for heart failure management. As the use of a validate 
questionnaire in a different cultural context can affect data 
interpretation our main objective is the Italian translation and 
linguistic validation of the Severe Heart Failure Questionnaire 
(SHF) and its comparison with the MLHF (Minnesota Living 
with Heart Failure) Questionnaire.
Methods. The SHF and “The Minnesota Living with Heart 
Failure Questionnaire” were translated. A consensus involving 
parallel back-translations was established among a group of 
cardiologists, psychologists and biostatisticians. SHF and MLHF 
were both administrated to a sample of 50 patients
Results. The patients’ median age was 63 years. Ace inhibitors 
therapy was administered in 88% of cases and betablockers 
in 56% of cases. Finally the Italian version of SHF correlates 
well with MLHF for all domains, except life satisfaction SHF 
domain.
Discussion: The Italian version of the SHF correlates well with 
MLHF for almost all domains and it represents a valid alterna-
tive for quality of life assessment in heart failure patients.
Introduction
The prevalence of symptomatic heart failure in the general 
European population ranges from 0.4% to 2.0% [1]. Heart 
failure in Italy is one of the most frequent causes of 
hospitalization (second medical DRG in Italy in 2001). 
Patients affected by heart failure have a compromised 
quality of life (QoL) [2-4]. Although decreasing mortal-
ity and improving the prognosis are major end points of 
the treatment, QoL is an important outcome indicator 
for heart failure management indeed, the “health related 
quality of life” could be considered one of the most 
important outcomes for the evaluation of treatments and 
improvement of the strategies [5, 6] in such patients.
In literature there is a substantial agreement in consider-
ing QoL a multidimensional phenomenon which could 
be analyzed through different perspectives: the physical, 
the psychological, the social and the economic well be-
ing or status of patients.
Health related QoL assessment could be done us-
ing generic or disease specific measures: the specific 
questionnaires allow the measurement of the clinical 
relevant domains, and are sensitive in identifying clini-
cal changes.
Several generic and specific disease questionnaires 
have been established to measure treatment effects but 
the assessment of QoL using a developed and validated 
instrument in a different cultural context can affect data 
interpretation [7].
The main objective of this study was the Italian transla-
tion and linguistic validation of the Severe Heart Failure 
Questionnaire (SHF).
Methods
THE QUESTIONNAIRES
SHF is a quite old and widely used [8], 26 items, disease 
specific health status measure for patients with conges-
tive heart failure which covers somatic, psychological, 
life dissatisfaction and physical limitations. Higher 
scores indicate lower heart related QoL [9].
“The Minnesota Living with Heart Failure Question-
naire” (MLHF) is a questionnaire which has been ap-
plied in most of the researches on heart failure patients: 
it is a 21 items questionnaire which using a 6 point 
response scale assess patient’s Emotional and Physical 
dimensions, and a General Total Score [10]. The Italian 
version of the MLHF has been produced by the MAPI 
Research Institute (www.mapi-research.fr) and it is 
available by them upon request.
THE TRANSLATION
The linguistic adaptation was performed following a 
standardized protocol. The linguistic validation is a 
linguistically validated translation which allows the as-
sessment in the relevant target countries: it is conceptu-
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ally equivalent to the original questionnaire ensuring the 
cross-cultural equivalence across translations.
The linguistic validation follows several steps. In our 
process, after the production of two independent transla-
tions by two professional translators’ native speakers in 
the target language, a professional English native trans-
lator produced the backward translation. Then the origi-
nal version, the developed Italian version and the back 
translation were compared discussing any discrepancy 
with expert cardiologists and psychologists. A cognitive 
debriefing, consisting in interviews with patients, was 
done to test the interpretability of the resulting version. 
Finally an international harmonization, consisting in a 
comparison of the target language version with the other 
and with the original one, was done to ensure conceptual 
agreement. The quality control was done by the IRCAB 
Foundation (Udine, Italy).
THE SAMPLE
The final version of the SHF was administered with 
MLHF [10] to a sample of 50 consecutive patients be-
longing to the heart failure outpatient clinic.
This is a tertiary care clinic and patients belong to all 
socioeconomic and cultural background.
STATISTICAL ANALYSIS
Data for both SHF and MLHF variables has been trans-
formed to have same range and interpretation, as indi-
cated in Guyatt et al. [11].
Data have been described using appropriate summary 
statistics (median, first and third quartile for continuous 
variables and percentages and counts for discrete vari-
ables). Spearman’s correlation between SHF Overall 
Summary Score and MLHF has been computed for 
several subgroups, according to major clinical variables. 
Difference in SHF and MLHF domains with respect to 
New York Heart Association Classification (NYHA) 
levels has been evaluated using a K-independent sam-
ples non-parametric median test. Spearman’s correla-
tion between each pair of MLHF and SHF domains has 
been computed.
Significance has been computed at 0.01, 0.05 level. All 
calculations have been performed using SPSS 7.0.
Results
See appendix 1 for the Italian version of the SHF.
Patients characteristic are summarized in Table I. The 
median age was 63 years. There were 40 men (80%) and 
10 women (20%). Only 8% of the patients was in NY-
HA class I whereas 52% of the patients were in NYHA 
class II (26 pts) and 40% in NYHA class III (20 pts). 
The median EF (left ventricular ejection fraction) was 
30%. The etiology was ischemic in 40% of cases, dilata-
tive in 36% of cases, and valvular in 24%. The majority 
of patients had a previous hospitalization in the last year 
(77%). Ace inhibitors therapy was administered in 88% 
of cases and betablockers in 56% of cases.
The Italian version of SHF correlates well with MLHF 
for all domains, except life satisfaction SHF domain 
(Tab. II).
Moreover SHF takes into account the changes in dif-
ferent NYHA class. The distribution of SHF “life sat-
isfaction” and “single item” domains are the only equal 
regarding to the NYHA I-II and NYHA III variables, as 
shown in Table III.
Finally, Table IV highlights the negative correlation 
between SHF “life satisfaction” domain and MLHF 
domains, being positive otherwise.
Discussion
This study reports the Italian translation and validation 
of the SHF that is a specific disease health related qual-
ity-of-life instrument with a well documented validity, 
reliability and responsiveness [12]. The questionnaire 
quantifies symptoms, physical limitations, social func-
tioning, patient’s sense of self efficacy and quality of 
life. The main characteristic of the SHF with respect to 
other instruments to evaluate QoL is the usage of the 
semantic differential to quantify patients’ responses. 
Each patient has to tick on a line his/her position be-
tween two extreme situations (worse, optimal). In the 
Tab. I. Patients’ descriptive statistics.
Patients characteristics
Age 63 (56; 69)*
Gender:
Males 80% (N = 40)
Females 20% (N = 10)
NYHA:**
I 8% (N = 4)
II 52% (N = 26)
III 40% (N = 20)
EF 30 (23; 35)*
Etiology:
Ischemic 40% (N = 20)
Valvular 24% (N = 12)
Dilatative 36% (N = 18)
Previous hospitalizations 77% (N = 37)
Therapy:
Ace inhibitors 88% (N = 44)
Beta blockers 56% (N = 28)
N = number of patients per category of variables; * = median [I quartile, 
III quartile]
** New York Heart Association Classification
 A functional and therapeutic classification for prescription of 
physical activity for cardiac patients.
 Class I: patients with no limitation of activities; they suffer no symp-
toms from ordinary activities.
 Class II: patients with slight, mild limitation of activity; they are com-
fortable with rest or with mild exertion.
 Class III: patients with marked limitation of activity; they are comfort-
able only at rest.
 Class IV: patients who should be at complete rest, confined to bed or 
chair, any physical activity brings on discomfort and symptoms occur 
at rest.
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original work the SHF is more sensitive to the important 
clinical change in the responsiveness cohort of patients 
than the MLHF or the SF-36 (Short-Form - 36 ques-
tions). The increased sensitivity to clinical change is 
summarized by the responsiveness statistics: the SHF 
physical limitation scale’s responsiveness is three times 
larger that the corresponding domains of the MLHF and 
SF-36. Some authors have noted that MLHF is sensitive 
to differentiates in symptom severity except in the most 
compromised patients group.
As reported by Green et al. [13], problems of meaning 
and interpretation could occur when respondents answer 
items of questionnaire. Respondents might fail to under-
stand a concept and thus give widely different interpreta-
tions to it. In particular, problem can arise with items that 
contain questions separated by the word ‘or’ and items 
that are considered not applicable to the respondent’s cir-
cumstances. Furthermore, the translation from English to 
other languages may result in a certain loss of concision, 
making questionnaire items more complex to understand. 
In spite of these potential drawbacks, the Italian version 
of the SHF correlates well with MLHF for almost all do-
mains. The two questionnaires also correlate well for EF, 
NYHA class, etiology, therapy and hospitalization.
Both the SHF and MLHF appear to be valid and reliable, 
however the SHF has the important advantage to avoid the 
patient to constrains his/her evaluation of the perceived 
quality of life into a 5 or 7 point Likert Scale. In this sense, 
the semantic differential used in the SHF is most appealing 
to limit cognitive biases in the patients’ indications.
Tab. III. Domains’ distribution of MLHF and SHF questionnaires regarding to the NYHA class.
NYHA I-II
(N = 30)
NYHA III *
(N = 19)
Overall *
(N = 49)
P-value
Minnesota Living with Heart Failure
Minnesota Emotional Score 92 (72, 100) 76 (68, 92) 88 (72, 96) 0.037
Minnesota Physical Score 92 (70, 97) 67 (35, 75) 82 (47, 95) 0.004
Minnesota Total Score 90 (70, 92) 73 (47, 81) 85 (51, 90) < 0.001
Severe Heart Failure Questionnaire
SHF Somatic Symptoms 85 (56, 94) 57 (30, 69) 73 (47, 92) 0.002
SHF Emotions 81 (62, 92) 67 (38, 71) 73 (54, 90) 0.002
SHF Life Satisfaction 47 (38, 64) 47 (42, 50) 47 (39, 54) 0.910
SHF Physical Symptoms 71 (57, 77) 49 (40, 60) 69 (46, 76) 0.002
SHF Single Item 60 (40, 80) 60 (40, 80) 60 (40, 80) 0.178
N = number of patients per category of variables; * = median [I quartile, III quartile]
Tab. IV. Spearman’s correlation between each pair of MLHF and SHF questionnaires’ domains.
Minnesota Living with Heart Failure
Minnesota
Emotional 
Score
Minnesota
Physical 
Score
Minnesota
Total
Score
SHF Somatic Symptoms 0.551* 0.641* 0.587*
SHF Emotions 0.569* 0.559* 0.509*
SHF Life Satisfaction -0.155 -0.110 -0.085
SHF Physical Symptoms 0.384* 0.578* 0.547*
SHF Single Item 0.450* 0.418* 0.416*
* = Correlation is significant at the 0.01 level (1-tailed)
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Appendix 1: SHF Italian version
La preghiamo di indicare con una X il punto nella scala sottostante che indica il suo stato di salute durante l’ultima settimana.
Esempio: molto per niente
Il dolore al torace ha limitato le sue attività giornaliere?
Le è mancato il respiro durante la notte?
Si è sentito affaticato?
Si è sentito esausto?
Si è sentito debole?
Si è sentito pigro?
Nel complesso, come le è sembrato il suo stato di salute nell’ultima settimana?
Ha avuto delle difficoltà nel prendere delle decisioni?
Si è sentito nervoso o preoccupato?
Si è sentito depresso?
Si è sentito agitato?
Ha avuto difficoltà a rilassarsi?
Si è sentito suscettibile?
Si è sentito più sensibile ai rumori (o alla confusione)?
Si è sentito soddisfatto della sua vita?
Si è sentito pessimista?
Ha trovato che la sua esistenza ha un significato?
Si è sentito di buon umore?
Si è sentito soddisfatto?
Di seguito troverà una serie di domande relative alle attività quotidiane. La preghiamo di indicare con una crocetta la risposta che 
corrisponde alla Sua situazione. Può scegliere solo una delle possibili risposte. La preghiamo di risondere a tutte le domande.
Esempio: senza difficoltà _
 quasi senza difficoltà _
 con qualche difficoltà _
 con parecchia difficoltà _
 è stato impossibile _
È stato in grado di uscire durante l’ultima settimana?
Durante l’ultima settimana, è stato in grado di scendere e salire le scale (circa 8 gradini)?
È stato in grado di camminare in salita ed in discesa durante l’ultima settimana?
È stato in grado di muoversi in casa durante l’ultima settimana?
È stato in grado di uscire per fare una passeggiata (meno di 1 km) durante l’ultima settimana?
È stato in grado di stare all’aperto durante l’ultima settimana?
È stato in grado di fare le faccende di casa (spolverare, cucinare, cambiare le lampadine ecc.) durante l’ultima settimana?
Con quante difficoltà il suo stato di salute è migliorato dopo aver iniziato la terapia?
×
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Minnesota Living with Heart Failure® Questionnaire
The following questions ask how much your heart failure (heart condition) affected your life during the past month (4 weeks). 
After each question, circle the 0, 1, 2, 3, 4 or 5 to show how much your life was affected. If a question does not apply to you, 
circle the 0 after that question.
Did your heart failure prevent you from living as you wanted 
during the pat month (4 weeks) by:
No Very 
little
Very 
much
1. causing swelling in your ankles or legs? 0 1 2 3 4 5
2. making you sit or lie down to rest during the day? 0 1 2 3 4 5
3. making your walking about or climbing stairs difficult? 0 1 2 3 4 5
4. making your working around the house or yard difficult? 0 1 2 3 4 5
5. making your going places away from home difficult? 0 1 2 3 4 5
6. making your sleeping well at night difficult? 0 1 2 3 4 5
7. making your relating to or doing things with your friends or
family difficult?
0 1 2 3 4 5
8. making your working to earn a living difficult? 0 1 2 3 4 5
9. making your recreational pastimes, sports or hobbies 
difficult?
0 1 2 3 4 5
10. making your sexual activities difficult? 0 1 2 3 4 5
11. making you eat less of the foods you like? 0 1 2 3 4 5
12. making you short of breath? 0 1 2 3 4 5
13. making you tired, fatigued, or low on energy? 0 1 2 3 4 5
14. making you stay in a hospital? 0 1 2 3 4 5
15. costing you money for medical care? 0 1 2 3 4 5
16. giving you side effects from treatments? 0 1 2 3 4 5
17. making you feel you are a burden to your family or friends? 0 1 2 3 4 5
18. making you feel a loss of self-control in your life? 0 1 2 3 4 5
19. making you worry? 0 1 2 3 4 5
20. making it difficult for you to concentrate or remember 
things?
0 1 2 3 4 5
21. making you feel depressed? 0 1 2 3 4 5
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